Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years; CHF with New York Heart Association class II-IV; left ventricular ejection fraction ≤ 35%; on beta blockers~Exclusion Criteria:~* Potassium \> 5.2 mmol/l; estimated glomerular filtration rate \< 30 ml/min/1.73 m2; systolic blood pressure \<100 mmHg or \> 180 mmHg; history of intolerance to recommended target doses of angiotensin converting enzyme inhibitors or angiotensin receptor blockers~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LCZ696 Condensed (Type: EXPERIMENTAL): Up-titration to LCZ696 200 mg twice daily (bid) over 3 weeks
- LCZ696 Conservative (Type: EXPERIMENTAL): Up-titration to LCZ696 200 mg bid over 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).